Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective, Randomized Clinical Trial of a Silver Eluting Dressing System for Prevention of Lower Extremity Revascularization Wound Complications
Brief Summary: This prospective, multi-institutional randomized clinical trial of a silver ion eluting dressing material compared to standard dry gauze for closed skin incisions after open surgical revascularizations for peripheral vascular occlusive disease. Based on the ability of the silver to lower the bacterial contamination of these vulnerable surgical skin incisions, the investigators hypothesize that immediate application of Acticoat Absorbent® as a post-operative dressing will reduce closed incisional wound complications in patients undergoing lower extremity revascularizations involving infrainguinal skin incisions compared to standard non-silver eluting dressing material.


Options:
A: Inclusion Criteria:

* Adult patient capable of informed consent who completes consent process
* Undergoing open (an incision below inguinal ligament) surgical procedure for peripheral arterial vascular disease in which it is anticipated that the incisions will be closed. Open cases combined with endovascular approaches acceptable.

Exclusion Criteria:

* Age less than 18
* Known allergy to silver or alginate
* Participation in another interventional clinical trial
B: Inclusion Criteria:

* Subject has a cataract and is expected to undergo unilateral clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber monofocal intraocular lens through an incision ≤ 3.5mm in width measured after IOL implantation using internal calipers.

Exclusion Criteria:

* Any intraocular inflammation in the study eye that was present during the screening slit-lamp examination or presence of ocular pain in the operative eye as rated on the pre-operative NRPS
* Previous surgery (laser or incisional) or ocular trauma to the operative eye or planned multiple procedures during cataract/IOL implantation surgery
* Potential BCVA in fellow eye worse than 20/40 as assessed by the clinical Investigator
* Active or history of chronic or recurrent inflammatory eye disease (iritis, scleritis, uveitis, iridocyclitis, rubeosis iritis), evidence of acute external ocular infections, intraocular infection, dysthyroid ophthalmopathy, nasolacrimal duct obstruction, active chalazion, uncontrolled blepharitis, uncontrolled and clinically significant dry eye syndrome, anything more than trace guttata (\>10 guttae in the central 6 mm of cornea), evidence of glaucoma/glaucoma suspect, corneal dystrophy or other ocular disease that would interfere with study evaluations
* Subject is currently receiving antineoplastic therapy
* Use of topical ocular steroids within 14 days and/or systemic steroids (excluding inhalants) within 30 days prior to surgery.
* Subject is an insulin-dependent diabetic or has background diabetic retinopathy (BDR), proliferative diabetic retinopathy (PDR) or compromised macular function
C: Inclusion Criteria:

* Patients underwent thyroidectomy in Srinagarind hospital, Khonkaen University

Exclusion Criteria:

* Patients with cervical lymph nodes metastases requiring neck dissection
* Patients that tissue pathology shown anaplastic carcinoma
* Patients with clinical or laboratory indicators of coagulation disorders
D: Inclusion Criteria:

* Diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims.
* Open surgical approach

Exclusion Criteria:

* Anastomotic leak
* Mortality
* Lost to follow-up

Answer: A